The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: A systematic review and meta-analysis

Archives of Internal Medicine

Volumn 171, Issue 20, 2011, Pages 1797-1803

  Gupta, Bhanu P ^a   Murad, M Hassan ^a   Clifton, Marisa M ^a   Prokop, Larry ^a   Nehra, Ajay ^a   Kopecky, Stephen L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN;

CARDIOVASCULAR RISK; COCHRANE LIBRARY; DISEASE SEVERITY; EMBASE; ERECTILE DYSFUNCTION; EXERCISE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; MEDITERRANEAN DIET; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEXUAL FUNCTION; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

ATTITUDE TO HEALTH; BEHAVIOR THERAPY; CARDIOVASCULAR AGENTS; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; DATABASES, FACTUAL; ERECTILE DYSFUNCTION; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHODIESTERASE 5 INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RISK REDUCTION BEHAVIOR; WORLD HEALTH;

EID: 81355164347     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.440     Document Type: Review

References (35)

1. NIH Consensus Development Panel on Impotence. NIH Consensus Conference. Impotence. JAMA. 1993;270(1):83-90.
2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50-56. (Pubitemid 29346774)
3. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003;139(3):161-168.
4. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med. 2000;30(4):328-338. (Pubitemid 30211093)
5. Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction.AmJ Epidemiol. 1994; 140(10):930-937. (Pubitemid 24355556)
6. Kupelian V, Link CL, McKinlay JB. Association between smoking, passive smoking, and erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Eur Urol. 2007;52 (2):416-422. (Pubitemid 46963449)
7. Barrett-Connor EL. Obesity, atherosclerosis, and coronary artery disease. Ann Intern Med. 1985; 103(6, pt 2)):1010-1019.
8. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000; 163(3):788-791. (Pubitemid 30091617)
9. Gades NM, Nehra A, Jacobson DJ, et al. Association between smoking and erectile dysfunction: a population-based study. Am J Epidemiol. 2005; 161(4):346-351. (Pubitemid 40256206)
10. Kaiser FE, Korenman SG. Impotence in diabetic men. Am J Med. 1988;85(5A):147-152. (Pubitemid 19012384)
11. Müller SC, el-Damanhoury H, Rüth J, Lue TF. Hypertension and impotence. Eur Urol. 1991; 19(1):29-34.
12. Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: apotentialprotectiveroleforstatinsand5-phos-phodiesterase inhibitors. J Am Coll Cardiol. 2008; 51(21):2040-2044. (Pubitemid 351689055)
13. Araujo AB, Hall SA, Ganz P, et al. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score? J Am Coll Cardiol. 2010;55(4):350-356.
14. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294(23):2996-3002. (Pubitemid 41817661)
15. Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18(4):405-410.
16. Esposito K, Giugliano F, Giugliano D. Erectile dysfunction in obese men [reply]. JAMA. 2004; 292(20):2467.
17. Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 2010;7(1, pt 1):156-165.
18. Lamina S, Okoye CG, Dagogo TT. Therapeutic effect of an interval exercise training program in the management of erectile dysfunction in hypertensive patients. J Clin Hypertens (Greenwich). 2009; 11(3):125-129.
19. Dadkhah F, Safarinejad MR, Asgari MA, Hosseini SY, Lashay A, Amini E. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res. 2010;22(1):51-60.
20. Herrmann HC, Levine LA, Macaluso J Jr, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med. 2006;3(2):303-308.
21. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49(6):822-830. (Pubitemid 27246947)
22. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51(12):1235-1241. (Pubitemid 29009523)
23. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
25. Stroup DF, Berlin JA, Morton SC, et al. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008- 2012. (Pubitemid 30214957)
26. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896- 1900.
27. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med. 1991;114(8):613-620.
28. Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences (MCID) in the erectile function (EF) domain of the International Index of Erectile Function (IIEF). http://download.journals .elsevierhealth.com/ pdfs/journals/0022-5347 /PIIS0022534711017757.pdf. Accessed July 22, 2011.
29. Berner MM, Kriston L, Harms A. Efficacy of PDE- 5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Int J Impot Res. 2006;18(3):229-235.
30. Jackson G. Erectile dysfunction: a marker of silent coronary artery disease. Eur Heart J. 2006; 27(22):2613-2614. (Pubitemid 44729854)
31. Hodges LD, Kirby M, Solanki J, O'Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61(12):2019-2025. (Pubitemid 350077416)
32. Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004; 110(1):22-26. (Pubitemid 38880129)
33. Inman BA, Sauver JL, Jacobson DJ, et al. A population- based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84(2):108-113.
34. Böhm M, Baumhäkel M, Teo K, et al. ONTARGET/ TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease(ONTARGET/TRANSCEND) Trials. Circulation. 2010;121(12):1439-1446.
35. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. A prospective study of risk factors for erectile dysfunction. J Urol. 2006; 176(1):217-221. (Pubitemid 43815415)